Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TELA Bio (TELA) Common Equity (2018 - 2025)

TELA Bio (TELA) has 8 years of Common Equity data on record, last reported at $1.6 million in Q3 2025.

  • For Q3 2025, Common Equity rose 124.82% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.6 million, up 124.82%, while the annual FY2024 figure was $28.5 million, 50.72% up from the prior year.
  • Common Equity reached $1.6 million in Q3 2025 per TELA's latest filing, down from $9.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $41.7 million in Q1 2021 and bottomed at -$6.3 million in Q3 2024.
  • Average Common Equity over 5 years is $17.4 million, with a median of $18.1 million recorded in 2025.
  • Peak YoY movement for Common Equity: surged 2694.36% in 2023, then plummeted 120.53% in 2024.
  • A 5-year view of Common Equity shows it stood at $20.1 million in 2021, then decreased by 28.82% to $14.3 million in 2022, then soared by 31.99% to $18.9 million in 2023, then skyrocketed by 50.72% to $28.5 million in 2024, then plummeted by 94.53% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $1.6 million in Q3 2025, $9.2 million in Q2 2025, and $18.1 million in Q1 2025.